Arvinas and Pfizer win FDA approval for Veppanu breast cancer treatment
Updated
Updated · MarketWatch · May 1
Arvinas and Pfizer win FDA approval for Veppanu breast cancer treatment
11 articles · Updated · MarketWatch · May 1
The US regulator cleared vepdegestrant for adults with certain advanced metastatic breast cancers that progressed after at least one endocrine therapy, ahead of its June 5 target date.
Arvinas said the decision marks the FDA's first approval of a PROTAC, or targeted protein degrader, therapy, a milestone the company said validates the approach's clinical potential.
The partners said they remain on track to choose a third party to help bring the drug to patients, while Arvinas shares rose 3.7% to $10.27.
How might the FDA's approval of the first PROTAC drug reshape the future landscape of targeted therapies and drug discovery?
What unanswered challenges remain for Veppanu’s real-world use, such as cost, access, or long-term resistance development?